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1ABSTRACT
Transplantation of interleukin-10-expressing human neural stem/progenitor cells for hypoxic-
ischemic brain injury in neonatal mice
Kwangsoo Jung
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Kook In Park)
Neonatal hypoxic-ischemic brain injury, a major cause of neonatal death and serious long-term 
neurological disability, results in extensive loss of cerebral parenchyma, neural cells, and connection. 
Although promising neuroprotective strategies have been studied, current management of HI brain injury 
has been limited supportive measures. The brain is a major target for inflammatory mediator actions and 
that inflammation or cytokines could be neurotoxic with direct effects on nerve cells. Although the 
mechanisms involved in inflammation-induced early brain injury are not clearly understood, recent 
evidence has shown that inflammatory responses in the fetus and neonate can contribute towards 
inflammatory cerebral white matter damage. 
Neural stem/progenitor cells are able to continuously self-renew and give rise to both neuronal and 
glial lineages. Upon implantation into an HI-injured brain, multipotent NSPCs not only engraft, migrate 
toward lesion sites and differentiate into neural cell types lost to injury, but also provide 
trophic/immunomodulatory factors, all of which are promising therapeutic options for neural repair.
Interleukin-10 is a typical anti-inflammatory cytokine that limits innate as well as adaptive immune 
2responses protecting the host from immune-mediated tissue damage. In a variety of different cell types, 
IL-10 not only mediates down-regulation of a broad spectrum of proinflammatory mediators such as IL-1, 
IL-6, IL-12, IFN-γ, and TNF-α, but also enhances alternatively activated microglia, thereby promoting 
tissue repair and remodeling.
In this study, we investigated the regenerative ability and action mechanisms of IL-10-transduced 
human NSPCs (IL-10-NSPCs) using a lentiviral vector implanted into the HI-damaged brain to develop a 
novel human NSPC-based gene therapy for neonatal HI brain injury. IL-10-NSPC showed increased 
proliferation, promoted neuronal differentiation over glial differentiation, anti-inflammatory effect on 
immune cells (microglia and macrophage), and changed polarization of microglia and macrophage from 
M1 to M2 type both in vitro and in vivo. Implanted IL-10-NSPCs reduced cerebral infarction volume, 
facilitated neurobehavioral recovery, reduced proinflammatory cytokines levels in the HI-injured brain, 
modulated inflammation through the polarization change of microglia and macrophage into anti-
inflammatory activation, and exhibited neuroprotection and angiogenesis by secretion of growth and 
angiogenic factors in vivo.
Based on these results, we postulate that IL-10-expressing human NSPCs facilitate functional recovery 
and neuroprotection after neonatal HI brain injury through synergistically enhanced anti-
inflammatory/immunomodulatory properties, neuronal survival and angiogenesis.
-------------------------------------------------------------------------------------------------------------------------------
Key words: neonatal hypoxia-ischemia brain injury, human neural stem/precursor cells, interleukin-10, 
transplantation, inflammation
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I. INTRODUCTION
Hypoxic-ischemic brain injury in newborn infants is a major cause of mental retardation, cerebral palsy, 
epilepsy, learning disabilities, and even death. Perinatal HI brain injury occurs in 2–4 per 1000 live term 
births, and approximately 60% of preterm HI infants suffer from permanent brain damages, although 
therapeutic hypothermia has been shown to improve recovery.1 The pathogenesis of the ischemic brain is 
not described only by the pathway of hypoxic cell death, but reflects continuous changes in genetic 
expression and levels of intrinsic oxidant radicals, growth factors, and inflammatory mediators such as 
cytokines, adhesion molecules, etc.2-4 Two phases of HI-induced neuronal death have been identified in 
both clinical and experimental studies.5,6 The immediate phase, primary neuronal death, is related to 
cellular hypoxia with exhaustion of the cell’s high-energy stores (primary energy failure). The second 
phase, delayed neuronal death,7 occurs after a latent period of at least 6 hr, and is associated with 
encephalopathy and increased seizure activity. Delayed neuronal death accounts for a significant 
proportion of final cell loss even after very severe insults. The mechanisms involved in delayed neuronal 
4death include excitotoxicity, apoptosis and microglial activation.8
Microglia are the resident immune cells in the brain and play an essential role in central nervous system 
development, maintenance and repair.9 However, altered microglial activity is associated with common 
human diseases, such as migraine, stroke, dementia, traumatic injury, epilepsy and Parkinson’s disease.10-
12 Microglia and macrophages are among the most potent modulators of CNS repair and regeneration;13
however, these cells are apparently double-edged swords in neurological recovery. On the one hand, 
activated microglia and macrophages promote brain recovery by clearing cell debris, resolving local 
inflammation and releasing trophic factors.13-16 On the other hand, these cells can hinder CNS repair and 
expand tissue damage.15,17,18 In vitro, classically activated (M1) microglia and macrophages release 
destructive proinflammatory mediators. In contrast, alternatively activated (M2) microglia and 
macrophages clear cellular debris through phagocytosis and release numerous protective and trophic 
factors.19,20
Regeneration of the CNS was previously considered impossible, despite the observation that focal 
cerebral ischemia promotes neurogenesis of endogenous neural stem/progenitor cells (NSPCs) in the 
subventricular zone of the lateral ventricles and subgranular zone of the dentate gyrus and induces their 
migration towards the ischemic boundary.21 Several studies have suggested that transplantation of 
exogenous NSPCs may have beneficial effects on the outcome following HI brain injury;22-24 however, 
the underlying recovery mechanisms are unknown.
Stem cell therapies have been attempted with various stem/progenitor cell preparations, including 
mesenchymal stem cells, multipotent astrocytic stem cells, and human umbilical cord blood cells.25
Among these, NSPCs show more restricted neural differentiation capabilities committed to specific 
subpopulation lineages. NSPCs are derived from specific spatiotemporal neural tissues or are generated
from embryonic and/or induced pluripotent stem cells.26,27 They have self-renewal capability, and can give 
rise to neurons, astrocytes, and oligodendrocytes.28,29 Human NSPCs (hNPSCs) can also be derived from
the developing human fetal brain between 8-20 wk of gestation.30,31 Multipotent NSPCs derived from the 
5developing or adult brain can be cultured and grown in the presence of mitogens, such as epidermal 
growth factor and fibroblast growth factor-2 either as monolayers or as free floating spherical aggregates 
(neurospheres).30-33 When NSPCs are implanted into a diseased or injured nervous system, they show not 
only preferential extensive migration to and engraftment within areas of discrete abnormalities but also 
the capability to replace diseased tissue appropriately (cell replacement effect).34-36 Apart from replacing 
lost cells, NSPC based therapy can also provide a regenerative microenvironment for other cells residing 
in diseased brains (bystander effect).23,37-39 Early studies aimed to establish whether exogenous NSPCs
could engraft and replace dying cells, and many showed that the donor cells survived and migrated 
toward the injury site. However, the effect derived from the net increase in cell numbers was generally 
negligible.25 Notably, the transplanted NSPCs were usually maintained with little differentiation, and it is 
not clear if these treatments resulted in fully functional and integrated neurons or glia.23,40,41
These findings suggest that the key mechanisms leading to therapeutic effects may be the release of 
neurotrophic and immunomodulatory/immunosuppressive factors.25,42 In the case of neonatal HI brain 
injury, stem cell treatment at different time points during the evolution of injury may allow a range of 
potentially complementary mechanisms to be targeted.
NSPC transplantation is a promising tool for regeneration of damaged brain in various neurological 
disorders,43 and has been investigated as a means to replace lost neurons and reconstitute lost brain tissue. 
Researchers have been eager to find efficient methods to transplant NSPCs into the brain and differentiate 
them into functional neurons. However, a number of studies have shown that NSPCs transplantation 
rarely results in a significant number of terminally differentiated neurons, although the transplantation 
induces significant functional recovery of the animal models. This raises the suspicion that the beneficial 
effect of NSPCs in disease models may be also attributable to alternative biologic properties, such as that 
transplanted NSPCs may attenuate deleterious inflammation, protect the CNS from degeneration, and 
enhance endogenous recovery processes.44 Several researchers have proposed that NSPCs transplantation 
may protect the CNS from inflammatory damage via an indirect mechanism rather than by direct cell 
6replacement.23 NSPCs rescue degenerating neurons by modulating the host environment by exert 
immune-like functions to induce apoptosis of encephalitogenic T cells,38,45 and suppress peripheral 
adaptive immune responses.46
Interleukin-10 is the most important cytokine with anti-inflammatory properties. It is produced by 
activated immune cells, in particular monocytes/macrophages and T cell subsets including regulatory T 
cells and T helper 1 cells. IL-10 acts through a transmembrane receptor complex, composed of IL-10 
receptor 1 and receptor 2, and regulates the function of many different immune cells, influencing several
functions of the microglia and monocytes/macrophages that are responsible for a positive role of these 
cells in both innate and specific immunity, such as release of immune mediators, antigen presentation, and 
phagocytosis. At the same time, it enhances the inhibitory, tolerance inducing, and scavenger functions of 
these cells. IL-10 also inhibits release of proinflammatory mediators from microglia and 
monocytes/macrophages and therefore inhibits LPS- and IFN-g-induced secretion of TNF-α, IL-1b, IL-6, 
IL-8, G-CSF, and GM-CSF.47,48
Several lines of evidence support that the cerebral expression of IL-10 is beneficial after experimental 
stroke, as transgenic mice overexpressing IL-10 in astrocytes, microglia, and endothelial brain cells 
showed smaller infarcts.49 IL-10 gene transfer using adenoviral vectors also reduced infarct volume in a 
model of photothrombotic ischemia in rats.50 Mice deficient in IL-10 showed larger infarctions after 
permanent middle cerebral artery occlusion.51 Animals deficient in IL-10 lack the anti-inflammatory drive 
of this cytokine, and therefore provide a good model to test whether and how IL-10 is involved in stroke 
outcomes. Consistent with these findings, low levels of circulating IL-10 in patients with lacunar stroke 
was associated with a worse outcome.52
In this study, we investigated the regenerative ability and action mechanisms of IL-10-transduced 
human NSPCs (IL-10-hNSPCs) implanted into the HI-injured brain to develop a novel hNSPC-based 
gene therapy for neonatal HI brain injury.
7II. MATERIALS AND METHODS
1. Human neural stem/progenitor cell culture
Human fetal tissue from a therapeutic abortus at 13 wk of gestation was obtained with full parental 
consent and the approval of the research ethics committee of Yonsei University College of Medicine, 
Seoul, Korea. The methods of acquisition conformed to NIH and Korean Government guidelines. The 
telencephalic region of CNS tissue was freshly dissected, dissociated in trypsin (0.1% for 30 min), and 
seeded into tissue culture-treated 100-mm plates (Corning, Tewksbury, MA, USA) at a density of 200,000 
cells/ml of serum-free growth medium, which consisted of a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium and Ham’s F12 (Gibco, Grand Island, NY, USA) supplemented with penicillin/streptomycin (1% 
vol/vol; GIBCO) and N2 formulation (1% vol/vol; GIBCO). Mitogenic stimulation was achieved by 
adding 20 ng/ml fibroblast growth factor-2 (FGF-2; Minneapolis, MN, USA) and 10 ng/ml leukemia 
inhibitory factor (Sigma, St Louis, MO, USA). Heparin (8 μg/ml; Sigma) was added to stabilize FGF-2 
activity. All cultures were maintained in a humidified incubator at 37°C and 5% CO2 in air, and half of the 
growth medium was replenished every 3-4 days. Passage of these cells was undertaken every 7-8 days by 
the dissociation of bulk neurospheres with 0.05% trypsin/EDTA (T/E; GIBCO).
2. Viral vector construction and preparation of IL-10-expressing human neural stem/progenitor cells
A second-generation of lentiviral vector containing EF-1α promoter was obtained from Trono lab (Prof. 
Didier Trono). We constructed recombinant lentiviral vectors bearing human IL-10 and green fluorescent 
protein (GFP) controlled by an internal ribosome entry site (IRES). The lentiviral vectors were produced 
by co-transfection of a transfer (pWPI-human IL-10-IRES-GFP), packaging (psPAX2) and envelope 
(pMD2.G) vector into 293FT cells (Thermo Fisher Scientific, Rockford, IL, USA) by calcium phosphate 
8transfection method. The infectious recombinant virus was titrated on HeLa cells by FACS (BD 
biosciences, San Jose, CA, USA). Lv-IL-10-IRES-GFP-infected hNSPCs were seeded onto cell culture 
dishes with 4-fold multiplicity of infection (MOI). IL-10 expression was checked by reverse transcriptase 
polymerase chain reaction (RT-PCR) and western blot.
3. Induction of experimental focal hypoxic-ischemic brain injury and cell transplantation
We used CD-1 mice and induced an HI injury. The right common carotid artery of anesthetized mice at
postnatal day 7 was ligated with 6-0 surgical silk. The incision was closed, and the animals were kept 
warm (37–38°C) until awake, then returned to their dams for 1.5–2 hr. The stabilized mice were placed in 
an acrylic chamber with a hypoxic atmosphere (8% O2 and 92% N2)and a 39°C heating pad for 1.5 hr. 
The animals recovered in room air and were returned to their dams. All mice received the same care and 
housing, and were evenly distributed between control and treatment groups. On day 3 after HI injury 
(postnatal day 10), the pups were anesthetized, and an incision was made through the dorsal midline of 
the scalp to inject IL-10-expressing hNSPCs (IL-10-hNSPCs or IL10-NSC group; 10 μl cell suspension at 
8×104 cells/μl), GFP-expressing hNSPCs (GFP-hNSPCs or GFP-NSC group), or vehicle into the HI-
injured site of each mouse brain with a glass micropipette (0.3 mm diameter). Cyclosporine (10 mg/kg) 
was intraperitoneally administered daily beginning a day before surgery until sacrifice. The procedures 
were approved by the Animal Care and Use Committees of Yonsei University College of Medicine (Seoul, 
Korea).
4. In vitro differentiation studies of IL-10-expressing human neural stem/progenitor cells
To identify IL-10-expressing hNSPCs, we stained IL-10-expressing hNSPCs (IL-10-hNSPCs), GFP-
expressing hNSPCs (GFP-hNSPCs), and compared the cell fates. IL-10-hNSPCs or GFP-hNSPCs was 
9trypsinized and plated on poly-L-lysine (10 μg/ml; Sigma)-coated eight-well chamber slides (Nunc) at 
8x104cells/well density and these two distinct hNSPCs were differentiated for 5 days. The cells were 
fixed with 4% paraformaldehyde (PFA) in 0.1 M PIPES buffer (Sigma) for 10 min, rinsed three times 
with phosphate-buffered saline (PBS), and treated as described below. The fixed cells were blocked with 
3% bovine serum albumin (BSA) and 10% normal horse serum with 0.2% Triton X-100 and incubated 
with the following primary antibodies: human nestin (1:200; Millipore, Billerica, MA, USA); GFAP 
(1:1000; DAKO, Glostrup, Denmark); STEM123 (1:500; StemCell INC); β-tubulin III (Tuj1, 1:500; 
Covance, Princeton, NJ, USA); Olig2 (1:500; Millipore); galactocerebroside (GalC, β 1:100; Sigma); 
Following rinsing in PBS, the cultures were incubated with species-specific secondary antibodies 
conjugated with fluorescein (Vector, 1:180) or Texas Red (Vector, 1:180), and DAPI (4', 6'-diamidino-2-
phenylindole, Vector) was used as the nuclear stain. After immunofluorescence staining, the percentage of 
immunoreactive cells was evaluated using a fluorescence microscope (Olympus Optical Co. Tokyo, 
Japan). For each group, we counted cells in 10 fields that included 100–500 cells. The total number of 
cells was evaluated by counting DAPI-positive nuclei and marker-positive cells.
To obtain total RNA of IL-10-hNSPCs or GFP-hNSPCs, hNSPCs were trypsinized and plated on poly-
L-lysine (10 μg/ml; Sigma)-coated 6-cm dish (Corning) at 1 x 106cells/dish and these two distinct 
hNSPCs were differentiated for 3 days to evaluate the gene expression of nestin, GFAP, Tuj1 and GalC. 
The differentiated hNSPCs were washed with PBS and resuspended in TRI Reagent (Molecular Research 
Center, Inc, Cincinnati, OH, USA).
5. 5-ethynyl-2′-deoxyuridine proliferation assay
Cell proliferation was estimated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation into newly 
synthesized DNA using Click-iT® Plus EdU Proliferation Kits for imaging and flow cytometry (Thermo 
Fisher Scientific) according to manufacturer’s instructions. Human NSPCs were seeded onto 6-well plates 
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at 1 × 106 cells per well in N2 media supplemented with 20 ng/ml fibroblast growth factor-2 (FGF-2; 
R&D), 10 ng/ml leukemia inhibitory factor (Sigma), heparin (8 μg/ml; Sigma), and EdU (2uM); and 
incubated for 24 hr. EdU treated hNSPCs were dissociated as single cells, fixed in 4% PFA in 0.1M 
PIPES solution, permeabilized using Perm/Wash Buffer (BD Biosciences, Cat #554723) and labeled with 
Alexa Fluor 647 Azide (Thermo Fisher Scientific). The percentage of cells incorporated with EdU was
analyzed by flow cytometry.
6. Oxygen-glucose deprivation
SH-SY5Y cells were dissociated and seeded on collagen (25 μg/cm2; Gibco) coated 24-well plates at 
80,000 cells/1 ml of 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 supplemented 
with 10 μM of retinoic acid (Sigma), then incubated for 5 days to differentiate neuronal cells. At 5 days 
after cell seeding, differentiated SH-SY5Y were indirectly co-cultured with 2×105 hNSPCs or fibroblast 
using Transwell with 0.4 μm pore insert (Corning) and incubated in an anaerobic chamber for 4 hr in 
Dulbecco’s Modified Eagle Medium (DMEM, high glucose. Gibco; Cat #11965084) or DMEM (no 
glucose, Gibco; Cat #11966025).
7. Lactate dehydrogenase assay
Cytotoxic effects were measured using the Cytotoxicity Detection KitPLUS (LDH, Roche Diagnostics 
Ltd., Rotkreuz, Switzerland) to quantify the release of LDH from SH-SY5Y cells incubated in oxygen-
glucose deprivation (OGD) conditions, according to the manufacturer’s instructions. All the samples were 
conducted in triplicate.
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8. BV2 cell culture
BV2 cells (murine microglia) were maintained in DMEM supplemented with 5% FBS and 
penicillin/streptomycin (1% vol/vol; GIBCO). Cells were seeded on 100-mm dish at 1×106 cells/10 ml 
culture media and split with fresh media daily. For stimulation, BV2 cells were treated with 100 ng/ml of 
lipopolysaccharide (LPS) for 24 hr and total RNA was extracted using TRI Reagent.
9. Isolation and culture of bone marrow derived macrophage
Femurs and tibias were isolated from mice. Both ends of the bones were cut with scissors and then 
flushed with 3–5 ml of 2% FBS in cold PBS with a 21G needle. Isolated marrow was passed through a 
21G needle 4–6 times to dissociate the cells, and then the dissociated cells were passed through a 70 um 
cell strainer to remove cell clumps, bone, hair, and other cells/tissues. The cells were incubated with 0.8% 
of NH4Cl solution in ice for 10 min to remove red blood cells, and were centrifuged at 500 g for 5 min at 
4°C. Cells were seeded at 1×107 bone marrow cells in 10 ml of bone marrow derived macrophage
(BMDM) growth media (10% FBS and 1x P/S in IMDM, Gibco, 12440-053) on 10-cm ultra-low culture 
dishes (Corning) supplemented with 10 ng/ml of M-CSF, then incubated for 7 days.
10. Preparation and treatment of conditioned media
IL-10-hNSPCs or GFP-hNSPCs were seeded at 1.2 × 107 cells/12 ml of N2 media on 100-mm culture 
dishes and incubated for 3 days. Media were then harvested and cleared by centrifugation at 3,000 g for 5 
min. The conditioned media (CM) was divided into aliquots and stored at 80˚C until use. To evaluate 
effects of the CM, BV2 cells were seeded at 2 × 106 cells/3 ml of culture media and incubated for 1 hr. 
Old media were then replaced with 100 ng/ml of LPS and CM. After a further 24 hr incubation, the BV2 
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cells were washed and collected in Tri Reagent for RNA.
11. Migration assay for chemotaxis
To determine the migration of BV2 or THP-1 to the hNSPCs, Lv-IL-10-hNSPCs, we used 
CytoSelect™ 24-well cell migration assay (5 µm, Fluorometric Format) (Cell Biolabs, Inc.), according to
the manufacturer’s instructions. Singly dissociated hNSPCs or fibroblast were seeded onto poly-L-lysine-
coated 24-well plates (lower chamber) at 500,000 cells/ml of 1:1 mixture of DMEM and Ham’s F12, then 
incubated for 24 hours. BV2 cells (50,000 cells/100 ul of the same media) were added into the upper 
chamber of the 5.0 mm porous Transwell and incubated for 4 hr in a cell culture incubator (upper 
chamber). Migratory cells attached to the bottom side of the Transwell were dissociated from the 
membrane by the addition of cell detachment buffer to the lower chamber. Detached cells were lysed and 
quantified using CyQuant® GR fluorescent dye and the FlexStation®3 Reader.
Migration of endothelial progenitor cells (EPCs) was assayed using a disposable 96well chemotaxis 
chamber (Neuro Probe, Inc., Gaithersburg, MD). Briefly, EPCs were harvested with 0.05% trypsin 
containing 0.02% EDTA, washed once, and suspended in endothelial cell basal medium-2 (EBM-2) at a 
density of 2 × 105 cells/ml. A membrane filter with 8 μm pores of the chemotaxis chamber was precoated 
overnight with 20 μg/ml rat-tail collagen at 4 °C, an aliquot (100 μL) of EPCs suspension was loaded into 
the upper chamber, and CM of GFP-hNSPCs or IL-10-hNSPCs was then placed in the lower chamber. 
After incubation of the cells for 12 hr at 37 °C, the filters were disassembled, and the upper surface of 
each filter was scraped free of cells by wiping it with a cotton swab. The number of cells that had 
migrated to the lower surface of each filter was determined by counting the cells in four locations under 
microscopy at ×100 magnification after staining with hematoxylin and eosin.
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12. Immunohistochemistry
The animals were anesthetized and transcardially perfused with cold PBS followed by cold 4% PFA in 
0.1 M PIPES solution. The brain was carefully extracted, fixed overnight in 4% PFA in 0.1 M PIPES 
solution at 4°C, and subsequently transferred to 30% sucrose solution at 4°C until embedding. Optimal 
cutting temperature compound was used to embed the brains, and 16 μm sections were cut on a freezing 
cryostat and stored at 20°C. For fluorescence immunohistochemistry, sections were first blocked with 10% 
normal donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and 3% BSA in 
PBS with 0.3% Triton X-100. Primary antibodies were incubated overnight at 4°C. Appropriate secondary 
antibodies were applied for 70 min at 37°C followed by three PBS washes before they were mounted. 
Primary antibodies included human nuclei (hNuc, 1:100; Millipore), Ku80 (1:200; Cell Signaling tech, 
Danvers, MA, USA), STEM101 (1:100; StemCell INC, Newark, CA, USA), STEM121 (1:500; StemCell 
INC), and human IL-10 (1:100; R&D systems) for tracing hNSPCs and anti-human nestin (1:200; 
Millipore, Billerica, MA, USA); Tuj1 (1:500; Covance, Princeton, NJ, USA), GFAP (1:1000; DAKO, 
Glostrup, Denmark), STEM123 (1:500; StemCell INC), and Olig2 (1:500; Millipore) for identifying 
hNSPCs differentiation patterns and anti-ionized calcium-binding adapter molecule 1 (Iba-1, 1:500; Wako, 
Osaka, Japan); and CD68 (1:100; BD Biosciences) for microglia. Secondary antibodies were conjugated 
to fluorescein, or Texas Red (Jackson ImmunoResearch Laboratories, Inc). Immunolabeled cells were 
observed with a fluorescence microscope (Olympus), and a Zeiss LSM 700 confocal microscope (Carl 
Zeiss, Oberkochen, Germany) was used to acquire Z-stacks to assess merged images.
To investigate the implanted hNSPC differentiation profile, 100 or more human nuclear antigen, 
STEM121 or GFP positive cells in the peri-infarct area were scored for: nestin as a marker of immature 
NSCs, GFAP and STEM123 as markers of astrocytes, Tuj1 as a marker of immature and mature neurons, 
and Olig2 as a marker of oligodendrocyte progenitors at 2 wk post transplantation (n=4–5 per group).
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13. Behavior test
Neurological severity score and cylinder tests were performed at 1, 2, 3, and 4 wk post transplantation 
in the following four groups of mice. We analyzed n=11–31 animals per group. The neurological 
functions of all animals were evaluated using the following five reflexes, with each exam scored as ‘0’ if 
the response was normal and ‘1’ if the animal showed an abnormal reflex:
(i) When the mouse was suspended by the tail above the ground (abnormal postures include 
rotating the body [torso twisting], and limb flexing [forelimb flexion]); 
(ii) When the mouse was placed on its side, it immediately turned over to rest in the normal 
position with all four feet on the ground (right reflection);
(iii) When the dorsum of the paw contacted the edge of the table, the mouse immediately placed 
their paw on the surface (placing reaction); and 
(iv) the mouse was placed on a board, and if the board was suddenly bounced, the mouse spread its 
toes (toe spreading).
In the cylinder test, all mice were located in an acrylic cylinder (10 cm diameter, 30 cm high) and 
recorded for 5 min. The video was used to evaluate how many times the mice placed their forelimbs on 
the cylinder walls, and limb use asymmetry (LUA) ratio was calculated as LUA (%) = [(non-impaired 
forelimb) – (impaired forelimb)] / [(non-impaired forelimb) + (impaired forelimb)] * 100. All tests were 
performed as a double blind.
14. Infarct volume measurement
We estimated lesion size as a percentage of the whole brain by using the following formula: [(area of 
contralateral hemisphere) - (area of remaining ipsilateral hemisphere)/(area of contralateral hemisphere) *
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100]. The area of both hemispheres was measured in eight serial coronal sections per brain (200 μm apart) 
stained with Hematoxylin Gill’s formula (Vector, Burlingame, CA, USA) and Eosin-Y (Sigma, St. Louis, 
MO, USA) using Virtual Microscope (Olympus BX51, Tokyo, JAPAN) and Image J (Broken symmetry 
software, NIH). The area of the infarct was averaged over the eight sections per animal and expressed as a 
percentage of total pixels within the microscope field. We analyzed n=7–11 animals per group at 4 wk 
post transplantation.
15. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay
The cryopreserved brain sections were fixed with 4% PFA in PBS for 20 min at RT and washed with 
PBS. The slides were permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate buffer for 2 min at 
4°C. After three washes, the sections were treated with Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) reaction mixture (Roche Applied Science) and incubated for 1 hr at 37°C. TUNEL 
positive nuclei at 4 wk post transplantation were microscopically analyzed.
16. Isolation of microglia and infiltrating immune cells from the brain
Brain mononuclear cells were isolated using a standard protocol described in detail previously.53,54
Briefly, mice were perfused with cold PBS, the ipsilateral hemisphere was removed, diced and
mechanically digested with Dounce homogenizer (Corning) in 7ml of RPMI 1640. Three ml of isotonic 
Percoll solution (Amersham) were added in the cell suspension to make a final 30% of Percoll. The cell 
suspension was gently laid on the surface of 70% Percoll solution and centrifuged (550 g, 30 min, 18°C). 
The cells in the interface between 30% and 70% of Percoll solution consisted of mononuclear cells, which 
were washed prior to experiments. The isolated cells were stained with CD11b antibody-conjugated with 
PerCP-Cy5.5 dye and CD45 antibody-conjugated with PE dye and were analyzed by LSRII (BD 
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Biosciences) flow cytometry to distinguish microglia and infiltrating macrophages from other immune 
cells.
17. Isolation of CD11b-positive cells from the brain
CD11b-positive cells in the injured brain, consisting of microglia and infiltrating macrophages, were 
isolated from the ipsilateral hemisphere of injured mice. Briefly, after perfusion with ice-cold PBS, brains 
were dissected, weighed, and enzymatically digested using the Neural Tissue Dissociation Kit P (Miltenyi 
Biotec, Germany) for 35 min at 37°C. Further processing was performed at 4°C. Tissue debris was 
removed by passing the cell suspension through a 40 μm cell strainer. After myelin removal (see below), 
cells were stained with CD11b antibody conjugated with magnetic beads (Miltenyi Biotec, Germany) in 
IMagTM buffer (PBS supplemented with 0.5% BSA and 2 mM EDTA) for 15 min. CD11b+ cells were 
separated in a magnetic field using MS columns (Miltenyi Biotec, Germany). The amounts of antibodies 
and magnetic beads were calculated based on the number of cells obtained after myelin removal, using 
the manufacturer’s guidelines. The CD11b-positive (bound on the column) and negative (effluent) 
fractions were collected and used for further analyses.
18. Area occupied by Iba-1- or CD68-immunoreactive microglia of the injured brain
Quantification of the area occupied by microglia was performed using Virtual Microscope (Olympus 
BX51, Tokyo, JAPAN) and Image J (Broken symmetry software, NIH). Images of Iba-1 
immunoreactivity from cerebral cortical and penumbra regions were captured by Virtual Microscope, and 
the area occupied by Iba-1 (for total microglia) or CD68 (for activated microglia) immunoreactivity was 
determined using Image J by measuring number of pixels above a set threshold value and expressed as a 
percentage of total pixels within the microscope field. We analyzed n=7–11 per group at 4 wk post-
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transplantation.
19. Complementary DNA synthesis, RT-PCR and quantitative Real-time PCR
One μg of total RNA isolated from samples was reverse-transcribed into cDNA using the Transcriptor 
First Strand cDNA Synthesis Kit (Roche) according to manufacturer’s instructions.
For reverse transcription PCR (RT-PCR), cDNA was amplified using Go-Taq polymerase (Promega, 
Madison, WI, USA) in a thermal cycler (Eppendorf, Happauge, NY, USA) according to the 
manufacturer’s instructions. PCR products were separated on a 1.5% agarose gel and stained with 
ethidium bromide. As a negative control, the extracted RNA was amplified with PCR without prior 
reverse transcription. The expression of PCR products was normalized relative to the expression of 
GAPDH.
Quantitative real-time PCR was performed in a total volume of 10 μl containing 5 μl of LightCycler®
480 SYBR Green I Master (Roche Diagnostics Ltd., Rotkreuz, Switzerland), 0.5 μM of each primer and 
50 ng of synthesized cDNA using a LightCycler® 480 instrument (Roche Diagnostics Ltd). The cycling 
conditions were: 95° C for 5 min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 10 
s. All the samples were performed in triplicate.
The expression levels of each mRNA expression were normalized to the housekeeping gene GAPDH 
or 18S-rRNA using LightCycler® 480 Software, Version 1.5 (Roche Diagnostics Ltd). Primer sequences 
were retrieved from the PrimerBank Database (http://pga.mgh.harvard.edu/primerbank/).55 Primer 
sequences are shown in Table 1.
Table 1. Sequences of primers for reverse transcription and real-time PCR
Gene Forward sequence (5’ → 3’) Reverse sequence (5’ → 3’)
Il1b TCCTGTGTAATGAAAGACGGCACA CCCAGGAAGACAGGCTTGTGC RT-
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20. Western blot analysis and enzyme linked immunosorbent assay
Eluted proteins of conditioned medium or lysates in naïve hNSPCs, GFP-hNSPCs, and IL-10-hNSPCs
were investigated by western blot analysis. Lysates were prepared with homogenization in Tissue Protein 
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Extraction Reagent (Thermo Fisher Scientific, Inc.) supplemented with protease inhibitors (Sigma-
Aldrich), and the homogenates were briefly sonicated to shear the DNA before centrifugation at 4°C for 1 
hr at 100,000 g. The supernatant was stored as the soluble fraction. Protein concentration was determined 
using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA) based on the Bradford assay. Proteins 
were resolved by sodium dodecyl sulfate/polyacrylamide gel electrophoresis under reducing conditions 
and transferred to nitrocellulose membranes, which were blocked in 5% nonfat milk in Tris-buffered 
saline containing 0.1% Tween20 (TBST) for 1 hr. After overnight incubation at 4°C with human NT3 
antibodies (Santa Cruz Biotechnology, Dallas, TX, USA), the membranes were washed in TBST for 20 
min and incubated at room temperature with peroxidase-conjugated anti-mouse or rabbit antibody 
(Jackson ImmunoResearch Laboratories) for 1 hr. The blot was washed in TBST for 20 min, treated with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific), and bands were detected 
using a LAS 4000 mini (GE Healthcare, Buckinghamshire, UK).
The injured brain tissues were homogenized with Precellys Lysing kits (Bertin technologies, Cat # 
CK14) and Precellys 24 tissue homogenizer (Bertin technologies) in solution containing PBS and 
cOmplete ULTRA Tablets protease inhibitor cocktail (Roche Life Science) at a ratio of 500 ul to 200 mg 
tissue. Samples were centrifuged at 19,000 g for 20 min at room temperature, and then supernatants were 
collected and stored at -80°C. The concentration of mouse TNF-α and IL-1β and human IL-10 were 
determined using DuoSet® ELISA Development Systems for mouse TNF-α and IL-1β and human IL-10
(R&D systems) according to the manufacturer’s protocol.
21. Statistical analysis
Statistical analyses were conducted with SPSS 20.0 (IBM Company, Somers, NY, USA). On 
parametric analysis, differences among multiple means with one variable were calculated by one-way 
ANOVA and the Bonferroni post hoc test, and differences between two means were estimated with 
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unpaired t-test. On non-parametric analysis, differences among multiple means with one variable were 
evaluated by Kruskal Wallis, and differences between two means were assessed with Mann-Whitney test. 
Only values with P < 0.05 were accepted as significant.
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III. RESULTS
1. Generation and Characterization of IL-10-expressing hNSPCs in vitro
IL-10-expressing hNSPCs (IL-10-hNSPCs) and GFP-expressing hNSPCs (GFP-hNSPCs) were 
generated by infection with lentiviral particles encoding the human IL-10 and GFP, and GFP only, 
respectively (Fig. 1A). We first characterized GFP-hNSPCs and IL-10-hNSPCs in vitro and found that 
they formed neurospheres and expressed GFP (Fig. 1B). Flow cytometry analysis confirmed that 95.8%
of GFP-hNSPCs and 89.8% of IL-10-hNSPCs were GFP positive (Fig. 1C). IL-10 mRNA and protein 
were strongly expressed only in IL-10-hNSPCs, but not in GFP-hNSPCs (Fig. 1D and E). IL-10 from the 
supernatants of IL-10-hNSPCs and GFP-hNSPCs was quantified by enzyme linked immunosorbent assay 
(ELISA). The concentration of IL-10 in IL-10-hNSPCs was 87.4±5.72 ng/ml (1×106 cells/2 ml of 
media/72 hr), whereas IL-10 was not detectable in GFP-hNSPC and hNSPC samples (Fig. 1F).
To compare the proliferation rate, we performed EdU labeling experiments on IL-10-hNSPCs and 
GFP-hNSPCs. Cells were cultured in N2 media containing mitogens and 2 μM of EdU, which is a 
thymidine analogue incorporated into the newly synthesized DNA. Twenty-four hr after EdU treatment, 
IL-10-hNSPCs and GFP-hNSPCs were dissociated into single cells, stained with Alexa Fluor® 647 azide
(Invitrogen) and analyzed by flow cytometry (LSR II, BD). IL-10-hNSPCs and GFP-hNSPCs exhibited 
33.1±1.39% and 47.4±0.35% EdU positivity among total cells, respectively (Fig. 1G). To confirm this
effect of IL-10 on proliferation, hNSPCs were cultured in absence or presence of 100 ng/ml of IL-10 
peptide, and then incubated for 24 hr with EdU. The percentage of EdU-positive hNSPCs was 
significantly increased in IL-10 peptide treated hNSPCs (22.9±0.43%) compared to control hNSPCs 
(19.6±0.19%) (Fig. 1H).
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Figure 1. Characterization of IL-10-expressing hNSPCs in vitro. (A) Structure of lentiviral vector 
carrying human interleukin-10 under the control of the EF-1α promoter and GFP as a reporter gene, 
placed under IRES control. (B) Bright filed and immunofluorescence microscopy of representative 
neurospheres of IL-10-hNSPCs and GFP-hNSPCs. GFP signal was stably expressed in GFP-hNSPCs and 
IL-10-hNSPCs. Scale bar=100μm. (C) Flow cytometry; 95.8% of GFP-hNSPCs (blue line histogram, left) 
and 89.8% of IL-10-hNSPCs (blue line histogram, right) were GFP positive. Non-infected cells (hNSPCs)
were used as a negative control (red line histogram). (D) RT-PCR was performed with the cDNA 
synthesized from mRNA of GFP-hNSPCs and IL-10-hNSPCs. Messenger RNA of IL-10 was only
detected in IL-10-hNSPCs, but not in GFP-hNSPCs. (E) Expression of the interleukin-10 protein on 
Western blot. IL-10 was only detected in conditioned media and cell lysates of IL-10-hNSPCs. (F) ELISA 
assay performed using the supernatants of cultured hNSPCs, GFP-hNSPCs and IL-10-hNSPCs. (G) EdU-
positive hNSPCs were significantly increased in IL-10-hNSPCs compared to GFP-hNSPCs (n=3 per 
group). (H) EdU-positive hNSPCs were significantly increased in 100 ng/ml of IL-10 peptide-treated 
hNSPCs compared to hNSPCs without IL-10 peptide treatment (n=3 per group). Data are presented as 
mean ± standard error of the mean (SEM). **P<0.01 between the two groups.
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2. Differentiation of IL-10-hNSPCs and GFP-hNSPCs in vitro
To examine the differentiation patterns of GFP-hNSPCs and IL-10-hNSPCs in vitro, 
immunocytochemical staining with various antibodies was performed at 5 days after cell plating in the 
culture dishes under differentiation conditions. GFP-hNSPCs and IL-10-hNSPCs showed 
immunoreactivity for the immature cell marker NESTIN (Fig. 2A and B; 91.3±1.95% vs 79.9±1.52%,
respectively, n=3), astrocyte markers GFAP (Fig. 2C and D; 81.7±0.71% vs 19.6±2.31%), early neuronal 
marker TUJ1 (Fig. 2E and F; 14.0±1.82% vs 34.9±4.27%), and oligodendrocyte precursor markers 
OLIG2 (Fig. 2G and H; 9.8±0.02 vs 5.0±1.56%).
The percentage of TUJ1 in IL-10-hNSPCs was significantly increased, whereas the percentage of 
NESIN, GFAP, and OLIG2 was significantly decreased in IL-10-hNSPCs versus GFP-hNSPCs (Fig. 2I).
Quantitative real-time PCR (RT-PCR) analysis of cultured cells under differentiation conditions
confirmed that TUJ1 mRNA level of IL-10-hNSPCs was significantly increased, whereas the mRNA 
level of GFAP and GALC (oligodendrocyte marker) were significantly decreased in IL-10-hNSPCs (Fig. 
2J).
These findings demonstrate that IL-10-expressing hNSPCs show neurogenesis at the expense of 
astrocyte and oligodendrocyte differentiation in vitro.
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Figure 2. The differentiation patterns of IL-10-hNSPCs and GFP-hNSPCs in vitro. (A–H) Representative 
images of cellular markers in IL-10-hNSPCs and GFP-hNSPCs, Scale bar = 100 μm. Arrow head 
indicates co-expression of OLIG2 and GFP. (I) Percentages of NESTIN-, GFAP-, TUJ1- and OLIG2-
positive cells among total GFP-positive cells were calculated in GFP-hNSPCs and IL-10-hNSPCs under 
differentiation conditions (n=3 per group). (J) Relative fold change of mRNA expression for NESTIN, 
GFAP, TUJ1 and GALC, was measured by qRT-PCR analysis under differentiation conditions (n=3 per 
group). Data are presented as mean ± SEM. *P<0.05 compared to the GFP-hNSPCs group.
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3. Engraftment and distribution of IL-10-hNSPCs following transplantation
To evaluate the migration and engraftment pattern of hNSPCs in the injured brain, we transplanted IL-
10-hNSPCs and GFP-hNSPCs into the damaged brain of mice exposed to HI at 3 days post injury. 
Animals were sacrificed and dissected at 2 or 4 wk post transplantation for immunohistochemistry
staining to detect grafted human cells with human specific Nuc (hNuc) and/or GFP antibodies. At 2 wk 
post transplantation, grafted hNSPCs could still be detected around the ischemic boundary zone of the 
ipsilateral hemisphere and in the external capsule and cortex of the contralateral hemisphere (Fig. 3E–H).
Transplanted cells were co-stained with hNuc and GFP antibodies (Fig. 3B–D). Most GFP-positive 
cells were present in the ischemic boundary zone (Fig. 3E and F), and a few hNSPCs were infrequently 
distributed in the external capsule (Fig. 3G) and cortex (Fig. 3H) of the contralateral hemisphere at 2 wk 
after injection. On the other hand, we could rarely detect GFP-positive cells by immunohistochemical 
analysis of the lesion area at 4 wk post transplantation. We have identified the expression of human 
specific IL-10 in IL-10-hNSPCs iv vivo, but human IL-10 protein was only observed in IL-10-hNSPCs 
transplanted mice (Fig. 3I–K show high magnification images, Fig. 3M–O show low magnifications 
images, and Fig. 3L show the orthogonal view from confocal z-series). However, we could not detect 
human IL-10 protein expression in GFP-hNSPCs in vivo (Fig. 3P–R).
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Figure 3. Engraftment and distribution of IL-10-hNSPCs in vivo. (A) Low-magnification view of stroke 
within the mouse brain. The black boxes in Fig. 3A represent regions for representative images at 2 wk 
post-transplantation. (B–D) Grafted cells into the brain co-expressed human-specific nuclei (hNuc; white) 
27
and GFP (green). (E–G) Most GFP-positive cells were found in the ischemic boundary zone (E) and 
spared hippocampal region (F), with a few cells infrequently detected in the external capsule (G) and 
cortex (H) of the contralateral hemisphere at 2 wk post transplantation. (I–K and M–O) Maximum 
Intensity Projection (MIP) images showed that IL-10-hNSPCs co-expressed human IL-10 (red) and GFP 
(green): (I–K) high magnification and (M–O) low magnification. (L) Orthogonal view from confocal z-
series confirmed that GFP (green) and human IL-10 (red) in cytoplasm were expressed in the same cell.
(P–R) GFP-hNSPCs did not express human IL-10 in vivo. Scale bar=50 μm (D), 200 μm (E), 100 μm (F-
H), 20 μm (K and L) and 25 μm (O).
4. Differentiation of IL-10-hNSPCs and GFP-hNSPCs in HI mice following transplantation
We examined the differentiation patterns of IL-10-hNSPCs and GFP-hNSPCs following transplantation 
into the ischemic lesion site of HI injured mice. In the brain of HI mice that received IL-10-hNSPCs, the
grafted cells expressed human NESTIN (78.4±0.47%; Fig.4A–D), GFAP (78.9±3.19%; Fig.4E–H), TUJ1
(45.5±1.85%; Fig. 4I–L) and OLIG2 (3.3±0.72%; Fig.4M–P). Compared to the GFP-hNSPC-transplanted 
HI mice, a significantly higher number of grafted cells differentiated into TUJ1-positive early neurons by 
27.4%, and a lower number of grafted cells expressed human NESTIN by 14.1% in the IL-10-hNSPCs-
transplanted group. There was no significant change in the percentages of GFAP positive astrocytes 
between GFP-hNSPCs and IL-10-hNSPCs groups (Fig. 4R). In both groups, few GFP-positive cells (less 
than 3%) expressed OLIG2 specific to oligodendrocyte progenitor cells.
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Figure 4. Differentiation of IL-10-hNSPCs in HI mice following transplantation. (A–P) GFP+ cells (green) 
co-expressed cell type-specific markers (red), such as NESTIN (A–D), GFAP (E–H), TUJ1 (I–L), and 
OLIG2 (M–P). White arrows indicate the co-expression of each marker and GFP. (D, H, L, and P) 
Orthogonal view from confocal z-series showed that GFP and cell type-specific markers were expressed 
in the same cell. Scale bar=20 μm (C and D), 50 μm (G, H, K, L, O and P). (R) Comparison of 
differentiation patterns between IL-10-hNSPC and GFP-hNSPC transplantation groups. *P<0.05
compared to GFP-NSC group. All bars represent mean ± SEM.
5. HI mice implanted with IL-10-expressing hNSPCs exhibit enhanced functional recovery
We monitored neurological performance using neurological severity scores (NSS) and the cylinder test
at 1, 2, 3, and 4 wk post transplantation. IL-10-hNSPCs injected HI mice (IL10-NSC group) showed 
significant functional recovery using NSS from 1 through 4 wk post transplantation compared to the H-H 
buffer injected group (vehicle group) and at 1, 3 and 4 wk post transplantation compared to the GFP-
hNSPCs-transplanted group (GFP-NSC). However, there were no significant NSS differences between 
intact and IL10-NSC groups, and vehicle and GFP-NSC groups at all time points (Fig. 5A).
In the cylinder test, the IL10-NSC group showed improved performance at 3 and 4 wk post
transplantation compared to the vehicle group and at 3 wk post transplantation compared to the GFP-NSC 
group. No significant changes were found between intact and IL10-NSC groups, and vehicle and GFP-
NSC groups at all time points (Fig. 5B).
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Figure 5. Effect of IL-10-hNSPCs on behavioral performances. IL10-NSC group showed significant 
differences in neurological severity score (A) and cylinder test (B) compared to the other groups. All data 
are presented as mean ± SEM. #P<0.05, ##P<0.01, ###P<0.001 compared to the intact group; **P<0.01, 
***P<0.001 compared to the vehicle group; †P<0.05, ††P<0.01, †††P<0.001 compared to the GFP-NSC
group; ¡P<0.05, ¡¡ P<0.01, ¡¡¡P<0.001 compared to the IL10-NSC group.
6. Transplantation of IL-10-hNSPCs reduces infarct size after HI brain injury
We investigated whether transplantation of IL-10-hNSPCs could facilitate amelioration of ischemic 
stroke. At 4 wk post transplantation, the percentages of infarct volume in the IL10-NSC, GFP-NSC, and 
vehicle groups were 37.6±4.63%, 50.4±3.95% and 57.6±2.86%, respectively, as determined by 
haematoxylin and eosin staining (Fig. 6A). Infarct size of the IL10-NSC group was significantly 
decreased by 20% compared to the vehicle group, but there was no significant change in infarct volume 
between GFP-NSC and vehicle groups (Fig. 6C).
We performed TUNEL staining to label apoptotic cells in the ischemic boundary zone at 4 wk post
transplantation. A significant decrease of TUNEL-positive nuclei was found in the IL10-NSC group
(8.4±1.15 nuclei/mm2) compared to the vehicle and GFP-NSC groups (21.1±2.33 nuclei and 19.3±2.98
nuclei/mm2, respectively). There was no significant change between vehicle and GFP-NSC group (Fig.
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6D).
These results suggest that IL-10-hNSPCs exert a neuroprotective effect in vivo.
Figure 6. Effect of IL-10-hNSPCs on infarct size. (A) Infarct size measured by haematoxylin and eosin 
staining at 4 wk post transplantation. (B) TUNEL-positive nuclei in the ischemic boundary zone at 4 wk 
post transplantation. White arrows indicate TUNEL-positive DAPI. (C) Cortical infarct size was 
significantly attenuated in the IL10-NSC group compared to the vehicle group (n=6–8 per group). (D) 
The number of TUNEL-positive nuclei was significantly in the IL10-NSC group compared to the vehicle 
and GFP-NSC groups (n=4–7 per group). *P<0.05 compared to the vehicle group; #P<0.05 compared to
the GFP-NSC group. All bars represent mean ± SEM.
7. Effects of IL-10-expressing human NSPCs on inflammation in vitro
Several lines of evidence suggest that neuronal injury related to inflammation can induce a cascade of 
immune responses that are involved in the pathogenesis of early brain injury.56-58 Animal models 
demonstrate several changes in proinflammatory cytokine expression in conjunction with neuronal 
32
damage.57,59 In these models, ischemia or hypoxia alone is not enough to cause cerebral damage, but
additional inflammatory signals contribute to cell death.60 Therefore, we investigated the effects of IL-10-
hNSPCs on modulation of inflammatory responses in vitro, such as proinflammatory cytokine expression, 
proliferation and migration of microglia, and polarization of primary monocyte by FACS.
First, we confirmed the elevated mRNA level of proinflammatory cytokines (TNF-α, IL-1b, IL-6, and 
iNOS) when BV2 cells were treated with 100 ng/ml of LPS (LPS/Media group) (Fig. 7A). IL-6 and iNOS
mRNA of the activated BV2 with GFP-hNSPCs CM (LPS/GFP-CM group) were significantly decreased
compared to LPS/Media group, although TNF-α mRNA in the GFP-CM treated group was reduced with a 
decreased tendency (P=0.052) compared to LPS-treated BV2 cells. There was no change of IL-1b
between the LPS/Media and LPS/GFP-CM group. The mRNA of proinflammatory cytokines (TNF-α, IL-
1b, IL-6, and iNOS) of the IL-10-hNSPCs CM-treated BV2 (LPS/IL10-CM) group were significantly 
decreased compared to the LPS/Media group, and TNF-α and IL-1b genes of the LPS/IL10-CM group were 
more decreased than the LPS/GFP-CM group (Fig. 7A).
We also used RAW264.7 (murine macrophage cell line) to confirm the effect on reduction of 
inflammatory cytokine expression (Fig. 7B). As BV2 microglial cells, proinflammatory cytokine genes 
were increased in 100 ng/ml of LPS-treated RAW264.7 cells. The mRNA expression level of TNF-α and 
IL-6 in the LPS/GFP-CM group was significantly reduced compared to the LPS-treated RAW264.7 cells, 
but IL-1b and iNOS levels of LPS/GFP-CM group were not changed compared to LPS-treated 
RAW264.7 with LPS. The gene expression levels of TNF-α, IL-1b and IL-6 in LPS/IL10-CM group were 
significantly decreased compared to LPS-treated RAW264.7 cells, and those of TNF-α and IL-6 treated 
with IL-10-hNSPCs CM were more decreased than the LPS/GFP-CM group. There was no significant
change of iNOS mRNA level among the LPS/Media, LPS/GFP-CM, and LPS/IL10-CM groups (Fig. 7B).
These results show that hNSPCs have the capacity to inhibit proinflammatory cytokine expression, and 
this effect was more enhanced by IL-10-hNSPCs (Fig 7A and B).
Next, we quantified proliferation of BV2 co-cultured with fibroblast, GFP-hNSPCs and IL-10-hNSPCs. 
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Using the Transwell system with 0.4μm pore size, we assessed the effect of secretary factors from IL-10-
hNSPCs or GFP-hNSPCs on microglial proliferation. The percentages of EdU-positive BV2, indirectly 
co-cultured with media only (BV2 group), fibroblast (BV2/Fibroblast) and GFP-hNSPCs (BV2/GFP-
NSC), were 71.0±0.26%, 71.2±0.44% and 68.3±1.00%, respectively, showing no significant changes
between these groups. However, BV2 with IL-10-hNSPCs (BV2/IL10-NSC) showed a significant 
decreased effect on proliferation (53.4% ± 2.74%) compared to the other three groups (Fig. 7C). Direct 
co-cultured BV2 with hNSPCs exhibited dramatic changes in comparison with the indirect co-culture 
system. The percentages of proliferation of BV2, directly co-cultured with only media, fibroblast, GFP-
hNSPCs and IL-10-hNSPCs, were 66.9% ± 0.35%, 43.1% ± 0.15%, 33.0% ± 0.63% and 5.9% ± 0.06%, 
respectively. Compared to the BV2/Fibroblast group, the percentages of EdU-positive cells were
significantly decreased in BV2/GFP-CM and BV2/IL10-CM groups by 10.1% and 37.2%, respectively. 
The BV2/IL10-CM group was more reduced than BV2/GFP-CM group (Fig. 7D).
These data show that not only secretary factors but also transmembrane proteins of IL-10-hNSPCs 
influence the proliferation rate of microglia, although we have not identified factors that inhibit 
proliferation.
Next, we estimated whether GFP-hNSPCs and IL-10-hNSPCs affected migration of BV2 and THP-1 
(human monocyte cell line) toward hNSPCs. Fibroblast, GFP-hNSPCs and IL-10-hNPCs were seeded 
onto 24 well culture dishes at 5 × 105 cells/well without mitogen for 24 h, and then 5×104 cells of BV2 
were added into 5μm pore Transwell placed on the 24-well dishes. After 4 hours BV2 cell seeding, 
migratory cells through the Transwell membrane were measured by Cyquant GR dye. Migration of BV2
and THP-1 (human monocyte cell line) toward both hNSPCs was significantly increased, compared to 
recruitment of those cells toward fibroblast or media, although IL-10 did not enhance or weaken the 
migratory capacities of BV2 and THP-1 (Fig. 7E and F). These data are consistent with a previous report 
that shows the chemotaxis of macrophages/monocytes is only marginally impaired by IL-10.61
We measured the polarization of macrophages isolated from mouse leg bones (femur and tibia) into 
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M1 (classically activation) or M2 (alternatively activation) phenotypes. We defined M1 macrophage as 
MHC class II+ and CD206- and M2 macrophage as MHC class II- and CD206+ among CD11b-positive 
cells by flow cytometry (Fig. 7G). The percentages of M1 macrophages induced by culture media, GFP-
hNSPCs CM and IL-10-hNSPCs CM were 9.4% ± 0.08%, 7.1% ± 0.03% and 3.3% ± 0.12%, respectively.
M1 macrophage induction was significantly decreased by CM of GFP-hNSPCs and IL-10-hNSPCs, and
the IL-10-hNSPCs CM-treated group were more decreased than the GFP-hNSPCs CM-treated group (Fig 
7H). In contrast, M2 macrophage induction was significantly enhanced with GFP-hNSPCs CM (52.5% ±
0.02%) and IL-10-hNSPCs CM (63.7% ± 0.06%) compared to the media only group (48.5% ± 0.07%). 
Thus, treatment with IL-10-hNSPCs CM had better efficacy on M2 induction than that of GFP-hNSPCs 
CM (Fig. 7I).
These data demonstrate that IL-10-hNSPCs have several effects on decreased expression of cytokines
from BV2 and RAW264.7, inhibited proliferation of murine microglial cell line and polarization of bone 
marrow derived monocytes into alternative activated macrophages. However, IL-10-hNSPCs does not 
affect migration of BV2 and THP-1.
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Figure 7. Effects of IL-10-hNSPCs on inflammation in vitro. (A, B) IL-10-hNPSCs suppressed LPS-
induced TNF-α, IL-1b, IL-6 and iNOS mRNA in BV2 (murine microglial cell line) and RAW264.7
(murine macrophage cell line). The cultures were treated CM from IL-10-hNSPCs (IL10-CM) or GFP-
hNSPCs (GFP-CM) supplemented with or without LPS (100 ng/ml) and incubated for 24 hours. Total 
RNA was extracted and subjected to real-time PCR quantification for expression of proinflammatory 
mediator genes (n=3 per group). *P<0.05, ***P<0.001 compared to the LPS-treated group; #P<0.05,
##P<0.01 compared to the GFP-CM group. (C, D) The percentage of EdU-positive BV2 in total cells was
calculated following treatment with CM from fibroblast, GFP-hNSPCs or IL-10-hNSPCs. (C) In the 
indirect co-culture by Transwell with 0.4μm pore size, the percentage of EdU-positive BV2 co-cultured 
with IL-10-hNSPCs (BV2/IL10-NSC) was more decreased than that of fibroblast CM- (BV2/Fibroblast)
or GFP-hNSPCs CM-treated BV2 (BV2/GFP-NSC). (D) In the direct co-culture, IL-10-hNSPCs and 
GFP-hNSPCs reduced the proliferation of BV2 co-cultured with fibroblast. IL-10-hNSPCs had better 
effect on proliferation compared to the BV2/GFP-NSC group (n=3 per group). ††† P<0.001 compared to
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the BV2 group; **P<0.01, ***P<0.001 compared to the BV2/Fibroblast group; ##P<0.01, ###P<0.001
compared to the BV2/GFP-NSC group. (E, F) BV2 or THP-1 (human monocyte cell line) cells, passed 
through Transwell with 5um pore size, were quantified by Cyquant GR dye, which binds to cellular 
nucleic acids, produces a large fluorescence and measures cell numbers. Migration of BV2 and THP-1 
into GFP-hNSPCs (BV2/GFP-NSC and THP-1/GFP-NSC, respectively) or IL-10-hNSPCs (BV2/IL10-
NSC and THP-1/IL10-NSC) were significantly increased, compared to migratory cells into fibroblast 
(BV2/Fibroblast and THP-1/Fibroblast). There was no significant difference in BV2 or THP-1 between 
the GFP-NSC and IL10-NSC groups (n=3 per group). *P<0.05, **P<0.01, ***P<0.001 compared to BV2 
group; #P<0.05, ##P<0.01 compared to the BV2/Fibroblast group. (G-I) Reduction of M1 macrophage 
and induction of M2 macrophage were observed when we treated conditioned media from IL-10-hNSPCs
(IL10-CM) and GFP-hNSPCs (GFP-CM) into primary macrophages. (G) Representative images of 
polarization of monocyte into M1 (MHC II-positive and CD206-negative fraction) or M2 macrophage
(MHC II-negative and CD206-positive fraction) by flow cytometry. (H, I) These changes were more 
significant in the IL10-CM group than the GFP-CM group (n=3 per group). All data are presented as 
mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 compared to the media only condition; ###P<0.01
compared to the GFP-CM group.
8. Effects of IL-10-hNSPCs during progression of brain inflammation in HI mice
Proinflammatory mediator expression is enhanced immediately after injury and is followed several 
days later by a period of enhanced expression of anti-inflammatory cytokines.62 While the immune 
response in the days and weeks after brain injury can benefit recovery by clearing cellular debris and 
producing neurotrophic factors, disproportionate expression of neurotoxic proinflammatory mediators in 
the first hours and days after injury may be detrimental.63 Therefore, we examined the expression of 
cytokines using quantitative real-time PCR for mRNA level and ELISA for protein level at 1 wk post-
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transplantation (Fig. 8A and B). Messenger RNA level of IL-1b, IL-6 and iNOS was significantly reduced 
in IL10-NSC group compared to the vehicle group, and IL-6 gene showed a significant decrease in the 
IL10-NSC group compared to the GFP-NSC group (Fig. 8A).
The protein level of TNF-α and IL-1β was measure by ELISA. Mouse TNF-α of IL10-NSC group 
(1.0±0.08 pg/μg) was significantly decreased compared to the GFP-NSC (1.5±0.03 pg/μg) and vehicle
(1.7±0.13 pg/μg) groups. Mouse IL-1β (0.15±0.011 pg/μg) was also significantly reduced in the IL10-
NSC group compared to the GFP-NSC (0.21±0.010 pg/μg) and vehicle (0.26±0.019 pg/μg) groups (Fig. 
8B).
We isolated immune cells from the HI injured brain using Percoll gradient (37%-70%) centrifugation at 
1 wk post transplantation. The isolated immune cells were stained with CD11b and CD45 antibodies,
analyzed by flow cytometry. Three different populations were defined: CD11b+/CD45low, 
CD11b+/CD45high, and CD11b-/CD45+ cells. The majority of isolated immune cells were CD11b-positive 
cells, with most being CD11b+/CD45low and some CD11b+/CD45high (Fig. 8C and D). CD11b+/CD45low
cells were significantly increased in the IL10-NSC group (75.2±9.89%) compared to the GFP-NSC group
(34.3±9.69%), and CD11b+/CD45high cells were decreased in the IL10-NSC group (7.1±3.21%) compared 
to the GFP-NSC group (21.7±6.20%) with almost formal significance (P=0.108). There were no 
significant differences in CD11b+/CD45low and CD11b+/CD45high cells percentage between the IL10-NSC 
and vehicle groups.
Using magnetic beads conjugated with CD11b antibodies, we specifically isolated CD11b-positive 
cells from the injured brain and analyzed for M1 (TNF-α) or M2 (Arginase 1 (Arg1), IL-10 and CD206)
marker genes by real-time PCR. Messenger RNA level of TNF-α was significantly increased in the IL10-
NSC group compared to the GFP-NSC group, but there was no significant difference between the IL10-
NSC and vehicle groups. Compared to the vehicle group, Arg1 was significantly increased in both IL10-
NSC and GFP-NSC groups, but CD206 was significantly enhanced in only the IL10-NSC group. 
Messenger RNA of IL-10 expressed in CD11b+ cells from IL10-NSC group was significantly increased 
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compared to vehicle and GFP-NSC groups (Fig. 8E).
To confirm these in vivo results, we co-cultured BV2 directly with media, GFP-hNSPCs or IL-10-
hNSPCs in vitro. In these in vitro data, CD86, a marker of classical activation,16,64 was not changed
among all groups. Compared to the media only condition (BV2 co-cultured with media), Arg1 mRNA 
expression level of GFP-NSC (BV2 with GFP-hNSPCs) and IL10-NSC (BV2 with IL-10-hNSPCs) 
groups were significantly increased more than 340 and 160 fold, respectively, although Arg1 was 
significantly decreased in the IL10-NSC group compared to the GFP-NSC group. Other markers of 
alternative activation, such as IL-10 and CD206, were significantly enhanced in the IL10-NSC group 
compared to the GFP-NSC group (Fig. 8F).
These data show that IL-10-hNSPCs inhibit gene expression and protein production of 
proinflammatory cytokines, deactivate the classically activated microglia, and augment mRNA expression 
of the alternative activation markers (Arg1, IL-10 and CD206) in vivo.
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Figure 8. Effects of IL-10-hNSPCs on modulation of inflammatory responses at 1 wk post transplantation. 
(A) Relative expression level of mouse cytokine mRNA by quantitative real-time PCR. (B) Quantification 
of mouse TNF-α and IL-1β proteins by ELISA in the ipsilateral hemisphere of HI brain at 1 wk post
transplantation (n=3–4 for quantitative real-time PCR and n=6–7 for ELISA per group). *P<0.05, 
***P<0.001 compared to the vehicle group; #P<0.05 compared to the GFP-NSC group. (C) The 
percentage of CD11b+/CD45low, CD11b+/CD45high, and CD11b-/CD45+ among total CD45-positive cells 
isolated from the HI brain at 1 wk post transplantation (n=4–5 per group). CD11b+/CD45low population of 
the IL10-NSC group was significantly increased compared to the GFP-NSC group. There were no 
significant differences for CD11b+/CD45high and CD11b-/CD45+ among all groups. #P<0.05 compared to
the GFP-NSC group. (D) Representative flow cytometry for CD11b+/CD45low, CD11b+/CD45high, and 
CD11b-/CD45+ in the HI brain of vehicle, GFP-NSC, and IL10-NSC groups at 1 wk post transplantation. 
(E) Phenotype of isolated CD11b-positive cells from the injured hemisphere at 1 wk post transplantation
was determined by quantitative real-time PCR analysis of M1 marker TNF-α, and M2 markers Arg1, IL-
10, and CD206 (n=4–5 per group). #P<0.05, ##P<0.01 compared to the vehicle group; !P<0.05, !!P<0.01 
compared to the GFP-NSC group. (F) In vitro microglial phenotype of BV2 co-cultured with media, GFP-
hNSPCs, or IL-10-hNSPCs directly was assessed by quantitative real-time PCR analysis of M1 marker 
CD86, and M2 markers Arg1, IL-10, and CD206 (n=3 per group). *P<0.05, ***P<0.001 compared to the
media only group; #P<0.05 compared to the GFP-NSC group All data are presented as mean ± SEM.
9. Effects of IL-10-hNSPCs on brain inflammation at late stage of HI brain injury
We analyzed the occupied area by Iba-1 in both hemispheres of HI mice at 4 wk post transplantation 
with H-H buffer, GFP-hNSPCs and IL-10-hNSPCs (vehicle, GFP-NSC, and IL10-NSC group, 
respectively). Representative images of Iba-1-positive cells (Fig. 9B) were captured in the boxes near the 
ischemic boundary zone of the ipsilateral hemisphere (a, b and c in Fig. 9A). The Iba-1-immunoreactive 
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area was significantly increased in both GFP-NSC and IL10-NSC groups compared to the vehicle group, 
and there was no significant change between the GFP-NSC and IL10-NSC groups (Fig 9B and D).
We stained with CD68 antibody to detect activated microglia/macrophages. The area occupied by 
CD68 for the GFP-NSC group was significantly increased in the ipsilateral hemisphere (P<0.05) and 
slightly increased in the contralateral hemisphere (P=0.081) compared to the vehicle group. In both sides 
of the brain, CD68+ area was significantly reduced in the IL10-NSC group compared to the GFP-NSC 
group. There was no significant change between the vehicle and IL10-NSC groups on both hemispheres 
(Fig. 9C and D).
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Figure 9. Effects of IL-10-hNSPCs on inflammation at late stage of HI brain injury. (A) A low-
magnification view of stroke within the mouse brain. The three black boxes in Fig. 9A represent the 
regions for representative images at 4 wk post transplantation. (B) Representative images of Iba-1-
positive cells for total microglia/macrophages near the ischemic boundary zone. (C) Representative 
images of CD68-positive cells for activated microglia/macrophages near the ischemic boundary zone. (D) 
The area occupied by Iba-1-immunoreactive microglia in the ipsilateral hemisphere of HI mice was 
significantly increased the IL10-NSC and GFP-NSC groups compared to the vehicle group. There was no 
change in area occupied by Iba-1-positive cells in the ipsilateral hemisphere between IL10-NSC and GFP-
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NSC groups. In the contralateral hemisphere of HI mice, there were no significant differences among 
vehicle, GFP-NSC and IL10-NSC groups. The area occupied by CD68-positive activated microglia in the 
ipsilateral hemisphere was significantly increased in the GFP-NSC group compared to the vehicle group,
and significantly decreased in the IL10-NSC group compared to the GFP-NSC group. There was no 
significant difference between the vehicle and IL10-NSC groups. In the contralateral hemisphere of the
HI brain, the CD68-positive area in the GFP-NSC group showed a strong increasing trend toward 
significance (P=0.081) compared to the vehicle group. There was a significant decrease of CD68-
immunoreactive area in the IL10-NSC group compared to the GFP-NSC group, but no significant 
differences between the vehicle and IL10-NSC groups (n=7–11 per group). *P<0.05 and **P<0.01
compared between the groups. All data are presented as mean ± SEM.
10. Effects of IL-10-expressing human NSPCs on neuroprotection in vitro
To address the neuroprotective effect of IL-10-hNSPCs and GFP-hNSPCs, LDH cytotoxicity assays 
were performed with differentiated-SH-SY5Y cells treated with retinoic acid. Human neuroblastoma SH-
SY5Y, originally derived from the SK-N-SH cell line,65 have been frequently used, either in their 
undifferentiated state,66-68 or in a neuron-like differentiated state after induction with all-trans-retinoic 
acid.69-72 SH-SY5Y cells were seeded onto 24-well dishes at 8×104 cells/well with 10 μM of retinoic acid 
and incubated in a humidified incubator at 37°C and 5% CO2 in air for 5 days. Old media was replaced
with fresh serum-free media and 0.4μm pore sized-Transwells were placed on the 24-well dishes. Media 
or 8×104 cells of fibroblast, GFP-hNSPCs and IL-10-hNSPCs were added into the upper chamber of the 
Transwell for 24 hours. The Transwells were then removed, and SH-SY5Y cells co-cultured with media, 
fibroblast, GFP-hNSPCs, or IL-10-hNSPCs (SH-SY5Y, SH-SY5Y/Fibroblast, SH-SY5Y/GFP-NSC, and
SH-SY5Y/IL10-NSC groups, respectively) were incubated under normoxic conditions in DMEM with 
glucose (non-OGD) or under anoxic conditions in DMEM without glucose (OGD) for 4 hours. SH-
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SY5Y/IL10-NSC group cells showed reduced cytotoxicity, compared to SH-SY5Y/Fibroblast and SH-
SY5Y/GFP-NSC groups under non-OGD condition and to the SH-SY5Y/Fibroblast group under OGD 
condition (Fig. 10A).
We, then, assessed the expression level of neuroprotection-associated genes of IL-10-hNSPCs and 
GFP-hNSPCs by qRT-PCR. The mRNA expression level of NGF, NT3, NT4 and BDNF were
significantly increased in IL-10-hNSPCs compared to GFP-hNSPCs (Fig. 10B).
These data also suggest that IL-10-hNSPCs exerts neuroprotective effects by secretary factors, such as 
NGF, NT3, NT4 and BDNF in vitro.
Figure 10. Neuroprotective effects of IL-10-hNSPCs in vitro. (A) Viability of SH-SY5Y cells co-cultured 
with fibroblast, GFP-hNSPCs and IL-10-hNSPCs (SH-SY5Y/Fibroblast, SH-SY5Y/GFP-NSC and SH-
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SY5Y/IL10-NSC groups, respectively) were assessed by measuring the LDH activity in the supernatants. 
Decreased cytotoxicity of the SH-SY5Y/IL10-NSC group only was observed, compared to the SH-
SY5Y/Fibroblast and SH-SY5Y/GFP-NSC groups under normoxic conditions, and to the SH-
SY5Y/Fibroblast group under OGD conditions (n=3 per group). *P<0.05 compared to the SH-
SY5Y/Fibroblast group; †P<0.05 compared to the SH-SY5Y/GFP-NSC group. (B) Relative expression 
level of NGF, NT3, NT4 and BDNF mRNAs from GFP-hNSPCs and IL-10-hNSPCs was quantified by 
qRT-PCR (n=3 per group). *P<0.05, **P<0.01 compared to the GFP-NSC group. All bars represent mean 
± SEM.
11. Effects of IL-10-expressing human NSPCs on angiogenesis in vitro
We performed cell migration assay of endothelial progenitor cells to investigate the angiogenic role of 
hNSPCs in vitro. Chemotactic migration of EPCs was dose-dependently enhanced by IL-10-hNSPCs CM, 
and it was more potent than that of GFP-hNSPCs CM (Fig. 11A). EPCs treated with vascular endothelial 
growth factor (VEGF) were used as a positive control in cell migration assay. To clarify candidates that 
induce angiogenesis, we assessed the expression level of angiogenesis and tissue remodeling-associated 
genes of IL-10-hNSPCs and GFP-hNSPCs by RT-PCR. The mRNA expression level of MMP1, MMP2, 
and PAI-1 were increased in IL-10-hNSPCs compared to GFP-hNSPCs (Fig. 11B).
These data also suggest that IL-10-hNSPCs exerts angiogenic effects by secretary factors in vitro, such 
as MMP1, MMP2 and PAI-1.
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Figure 11. Angiogenesis effects of IL-10-hNSPCs in vitro. (A) Dose-dependent effects of GFP-hNSPCs
CM and IL-10-hNSPCs CM on chemotactic migration of EPCs. Migratory cells were quantified under
microscopy at × 100 magnifications after staining with hematoxylin and eosin (n=4 per group). (B) 
Relative expression level of MMP1, MMP2, and PAI-1 mRNAs from GFP-hNSPCs and IL-10-hNSPCs 
was observed by RT-PCR. *P<0.05 compared between the groups. All data are presented as mean ± SEM.
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IV. DISCUSSION
Microglial activation is the initial step in inflammatory responses of the CNS to various stimuli, such as
stroke73 and hypoxic-ischemic brain injury.74 This initial step amplifies the inflammatory response in the
ischemic brain. The microglial population is heterogeneous, and a subpopulation of microglia protects 
against stroke: injury is exacerbated after depletion of the proliferative microglia75 and ameliorated after 
injection of microglia into the ischemic brain.76 In other neurological disorders, appropriately activated 
microglia may also protect neurons from damage induced by resident or infiltrating cells, such as spinal 
cord injury,19,77-79 traumatic brain injury80-82 and stroke.83-85 Previous studies have shown that 
transplantation of neural stem cells can modulate cerebral inflammation and protect the brain from 
degeneration.38,45,46,86 However, transplantation of neural stem cells in neonatal HI brain is not sufficient 
to decrease the infarct volume, although these cells recover functional impairment.87-90 Several studies 
have suggested that neural stem cells combined with other treatments, such as chondroitinase ABC89 or 
mild hypothermia,90 are more effective against HI brain injury in terms of both improved neurological 
function and reduced infarct volume, but not when neural stem cells are administered alone. Therefore, 
we hypothesized that hNSPCs combined with human IL-10 would attenuate HI brain injury in immature 
mice by modulating inflammation causing the secondary injury.
To confer a strong anti-inflammatory capacity to hNSPCs, we transduced these cells with IL-10 using 
lentiviral vectors. Human NSPCs, genetically modified to express IL-10, release it stably, until the cells 
are diminished in vivo. IL-10-hNSPCs can be specifically located and express a transgene to locally 
modulate inflammation in the damaged site, because of their homing properties toward brain injuries.91,92
We also showed that transplantation of IL-10-expressing hNSPCs after neonatal HI brain injury can be 
very effective. IL-10-hNSPCs transplantation reduced lesion size significantly and markedly improved 
functional outcome.
We established IL-10-hNSPCs infected by lentiviral vectors encoding human IL-10, and characterized 
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these cells in vitro using Western blot, ELISA, quantitative real time-PCR, immunocytochemistry and 
flow cytometry. While most hNSPCs transduced by IL-10- or GFP-encoded lentiviral vectors stably 
expressed GFP, IL-10 was only expressed in IL-10-hNSPCs, evaluated by RT-PCR, Western blot and 
ELISA.
We measured the proliferation rate of IL-10-hNSPCs and GFP-hNSPCs. The EdU uptake was 
significantly enhanced in IL-10-hNSPCs. Interleukin-10-expressing hNSPCs were affected by IL-10 
released from themselves, acting in both an autocrine and paracrine manner. To confirm the effect of IL-
10 on hNSPCs proliferation, we treated these cells with IL-10 peptide, and the percentage of EdU-
positive hNSPCs was significantly increased. These data show that IL-10 can affect hNSPCs proliferation.
Although we have not demonstrated the precise molecular mechanism of IL-10 in promoting the 
proliferation of hNSPCs, several studies have shown that IL-10 affects proliferation of neural stem cells 
in vitro and increases the population of progenitors in the subventricular zone in vivo.93-95 Pereira et al.95
demonstrated that Erk signaling was activated by IL-10 in neural progenitor cells, and it had been 
previously reported that activating phosphorylation of Erk1/2 promotes proliferation of neural stem 
cells.96 Thus, we can infer that hNSPCs proliferation is induced via activation of the Erk1/2 signaling 
pathway by IL-10.
While hNSPCs possess the potential to differentiate into neurons, IL-10-hNSPCs differentiate into 
more neurons than GFP-hNSPCs, both in vitro and in vivo. The mechanism underlying IL-10-induced 
neural cell differentiation is not clear; it is possibly by induction of neurotrophic factors such as BDNF 
and NT-3. IL-10 production has been positively correlated to BDNF and NT-3 production, which promote 
neuronal proliferation, survival, and differentiation,97,98 and reduce astrogliosis.99 We also found that 
BDNF and NT-3, as well as NGF and NT-4, were induced in IL-10-hNSPCs cultures. The astrocyte 
marker, GFAP, was significantly decreased in IL-10-hNSPCs compared to GFP-hNSPCs in vitro, 
whereas there was no difference in the percentages of GFAP-positivity between IL-10-hNSPCs and GFP-
hNSPCs in the ischemic brain in vivo. Transplantation studies in various neurodegenerative disease 
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models support that the extent of neuronal or glial differentiation of hNSPCs depends on both local 
microenvironmental signals of host brain and intrinsic programs of the grafted cells.100,101 There are many 
other variables that may be involved in the differentiation of grafted hNSCs in injured brain, such as 
growth and inflammatory factors that regulate neurogenesis in the developing and adult brain.102
Astrocyte differentiation of neural stem/progenitor cells is enhanced by TNF-α and IL-1β in vitro and 
brain inflammation related to neurological diseases.103-105 This discrepancy of astrocyte differentiation 
between in vitro and in vivo is probably due to the inflammation of the HI brain.
In terms of differentiation in vitro and in vivo, the sum of all quantification markers of hNSPCs often 
reported more than 100%, suggesting there was overlap between some markers.41,106,107 In fact, nestin has 
been found to co-localize with OLIG2, TUJ1 and/or GFAP. In addition, several studies have observed 
differentiation failure of engrafted hNSPCs following transplantation.39,40,108-111 Thus, these findings mean 
that some of the grafted cells in this study express both neuronal (TUJ1) and glial (GFAP) cell markers
suggesting their immature state in vitro and in vivo.
Our data show that interleukin-10-expressing hNSPCs have superior anti-inflammatory effects than 
GFP-hNSPCs on activated microglia and macrophages in vitro. The expression level of proinflammatory 
cytokines mRNA from BV2 and RAW264.7 cells was more decreased by treatment with IL-10-hNSPCs
conditioned media. The supernatants of IL-10-hNSPCs significantly reduced the proliferation rate of 
microglia, and IL-10-hNSPCs resulted in more decreased proliferation of microglia when microglia were
directly co-cultured with GFP-hNSPCs or IL-10-hNSPCs. Our previous data show that not only secretory 
factors but also hNSPCs transmembrane molecules are related to microglial deactivation, and these 
effects in particular are more enhanced by cell-to-cell contact.106 CD200 and CD47 constitutively 
maintain microglia in a resting state and impede their proinflammatory activity.106,112
We also assessed the impact of IL-10-hNSPCs on monocyte/macrophage polarization in vitro. 
Enhanced M2 and impaired M1 type polarization were observed in IL-10-hNSPCs CM-treated bone 
marrow derived macrophages. According to the other reports, M2c type macrophages are known as 
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deactivated or regulatory macrophages113 and are elicited by IL-10 and TGF-β; M2c macrophages appear 
to be involved in tissue remodeling.114-116 We have previously identified the expression of TGF-β mRNA 
from hNSPCs.106 Therefore, we propose that IL-10-hNSPCs enhance M2 polarization of bone marrow 
derived macrophages by IL-10 and TGF-β in vitro.
Using an in vivo model of neonatal HI brain injury, we verified the results from the in vitro study.
Ivacko et al.117 demonstrated that activated microglia begin to accumulate within 4 hours after injury and 
accumulation of lectin-positive cells peak at 2–4 days post injury in perinatal rats, although they did not 
distinguish microglia and macrophages from lectin-positive cells. Appropriately activated microglia and 
macrophages at sub-acute injury stage may also protect neurons from damage induced by resident or
infiltrating cells. Therefore, we transplanted IL-10-hNSPCs to regulate microglial activation at 3 days 
post injury, and analyzed inflammation and microglia/macrophages activation at 7 days post
transplantation in vivo. To assess the modulating effects of IL-10-hNSPCs on inflammation in the 
ischemic brain in vivo, the brains were dissected to quantify cytokine levels by real-time PCR and ELISA, 
as well as polarization of microglia and/or macrophages by real-time PCR and flow cytometry at 7 days 
post transplantation. Protein and gene levels of IL-1β were reduced in IL-10-hNSPCs-injected mice 
compared to GFP-hNSPCs-injected mice. TNF-α protein level was significantly decreased in the IL10-
NSC group compared to the vehicle and GFP-NSC groups, although the gene level of TNF-α did not 
change significantly among the group. The correlation between mRNA and protein quantity depends on 
various biological and technical factors,118 and these constraints make the correlation between mRNA and 
protein worse.
Numerous experimental studies have highlighted depicted the pivotal response of resident microglia
and infiltrating monocyte-derived macrophages to either the development of the brain injury or its 
resolution leading to conflicting interpretation of their protective or deleterious contribution in 
stroke.119,120 In neonates, however, the infiltration of neutrophils, lymphocytes and macrophages
following ischemia and focal stroke may be less profound121-123 or only briefly present in the 
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parenchyma.124 Several lines of evidence support that not only microglia can be distinguished from 
macrophages and other immune cells, but also resting microglia can be discriminated from activating 
microglia using CD11b and CD45 membrane antigens.125-129 To date, the most common characterization
of resting microglia and activating microglia/infiltrating macrophages are CD11b+/CD45low and 
CD11b+/CD45high, respectively, using flow cytometry.126,128-131 Compared to adult stroke, infiltration of 
circulating macrophages/monocytes across the blood brain barrier is relatively low during the acute injury 
phase in neonates.121-123 It remains poorly understood whether leukocyte immaturity at the time of insult
or a distinct gene expression pattern of selectins, and cytokines/chemokines account for the difference. 
The issue regarding infiltration of macrophages and monocytes into neonatal ischemic brain remains 
unresolved.86,123,132-134
Therefore, we supposed that CD11b+ cells were resting microglia and activated microglia/infiltrating 
macrophages at sub-acute stage injury stage in the HI brain of neonates. We identified 3 different 
populations by flow cytometry with CD11b and CD45 antibodies: CD11b+/CD45low (resting microglia), 
CD11b+/CD45high (activating microglia/infiltrating macrophages) and CD11b-/CD45+ (other infiltrating 
cells). Our flow cytometry data show that microglial activation and infiltrating of macrophages in the 
ischemic brain were inhibited by IL-10-hNSPCs at 1 wk post transplantation, whereas GFP-hNSPCs 
could not deactivate microglial activation or inhibit infiltration of macrophages in the injured brain.
To identify the phenotype of microglia/macrophages, we isolated CD11b+ cells in the brain by real-
time PCR, using CD11b antibodies conjugated with magnet beads, and compared differential gene 
expression levels of M1 and M2 microglia markers among vehicle, GFP-NSC and IL10-NSC groups. 
Intriguingly, M2 markers, such as Arg-1, IL-10 and CD206, were dramatically increased in 
microglia/macrophages isolated from the IL10-NSC group compared to the vehicle group. None of IL-10 
and CD206 mRNA was changed between vehicle and GFP-NSC groups, but Arg-1 was increased in the 
GFP-hNSPCs group compared with the vehicle group.
To confirm these in vivo results, we cultured BV2 cells with GFP-hNSPCs, IL-10-hNSPCs or culture 
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media. Our in vitro data showed that the expression levels of IL-10 and CD206 were significantly 
enhanced in microglial cells co-cultured with IL-10-hNSPCs. Although decreased in the IL-10-hNSPCs
group compared to the GFP-hNSPCs, arginase-1 gene level was induced in both IL-10-hNSPCs and GFP-
hNSPCs group compared to BV2 cells without hNSPCs.
Taken together, these results indicate that IL-10-hNSPCs regulate protein production and gene
expression levels of cytokines via modulating polarization of microglia toward alternative activation or 
deactivation in vivo, and these anti-inflammatory effects are more enhanced in IL-10-expressiong 
hNSPCs than GFP-hNSPCs at the sub-acute stage of injury.
We evaluated whether the modulatory effects of IL-10-hNSPCs on inflammation of the ischemic brain 
were sustained until sacrifice. Using immunohistochemistry with Iba-1 antibody, the area occupied with 
microglia in the HI brain was quantified at 4 wk post transplantation. Contrary to our expectation based 
on the increase of resting microglia by IL-10-hNSPCs at 1 wk post transplantation, the area occupied by 
Iba-1-positive microglia was significantly increased in both GFP-NSC and IL10-NSC groups compared 
to the vehicle group. These data are consistent with previous studies that showed an increase in microglia 
or microglial activation in the neonatal ischemic or healthy brain that received neural stem cells (NSCs) 
or human NSCs.86,88,135
To investigate whether these microglia were deactivated at 4 wk post transplantation, we used CD68 
antibody to detect activated microglia. CD68 is widely used as a microglia/macrophages marker for 
activation or M1 polarization,64,136 although no previous reports describe the existence of a single, specific 
marker for microglia, macrophage or activation status of these cells.137-139 IL-10-hNSPCs effectively 
deactivated microglial activation as indicated by measuring the area occupied by CD68-positive cells 
compared to the GFP-NSC group, but not to the vehicle group. Our staining data using Iba-1 and CD68 
antibodies showed that IL-10-hNSPCs effectively deactivated activated microglia, although the increased 
area occupied by microglia is seen in both IL-10-hNSPCs- and GFP-hNSPCs-transplanted groups.
Transplantation of NSPCs can not only reduce conventional inflammatory responses, but also improve 
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neuroprotection by secretary factors in various neurological diseases.97-99,140-142 Neurotrophic factors are 
important for the survival, maintenance, and regeneration of specific neuronal populations in the 
brain.143,144 A decrease in neurotrophic factors has been associated with the pathology of several 
neurodegenerative diseases and their physiological symptoms.145,146 Various studies have demonstrated
that neurotrophic factors can protect neurons against a variety of pathological insults, including 
ischemia147,148 and neurotoxins, such as Alzheimer’s disease.149-151 Angiogenesis is related to neurogenesis 
and plays a critical role in injured tissue repair.152 It is important that intracerebral transplantation of 
hNSPCs can induce angiogenesis, because angiogenesis is implicated in the formation of neurovascular 
units and functional recovery after ischemic stroke and thus may significantly contribute to a favorable 
clinical outcome for stroke patients.153 Angiogenesis involves the migration and proliferation of pre-
existing, fully differentiated endothelial cells.154 In addition, circulating EPCs may home to sites of 
neovascularization and differentiate into endothelial cells in situ.155-160 Mobilization of EPCs augments 
neovascularization of ischemic tissue155,160-163 and may be clinically relevant in the setting of tissue 
ischemia.162,164,165
In addition to the anti-inflammatory properties of IL-10-hNSPCs, we identified that not only the 
neuroprotective effects on neuron-like SH-SY5Y cells but also the angiogenic effects on endothelial 
progenitor cells were enhanced by the secreted factors from IL-10-hNSPCs in vitro. Although the 
therapeutic potential of neurotrophic and angiogenic factors was not directly identified in the ischemic 
brain, many publications suggested that neurotrophic166-169 and angiogenic factors153,162,164,165 ameliorate 
neonatal HI brain injury. Therefore, we cannot rule out the possibility that the therapeutic effects in 
ameliorating ischemic brain injury are associated with neurotrophic and angiogenic factors secreted from 
IL-10-hNSPCs.
Transplantation of IL-10-hNSPCs in neonatal HI mice produced improvement of functional recovery as 
determined by NSS and the cylinder test, and reduction of infarct volume. In the IL-10-hNSPCs-
transplanted group, neurological function assessed by NSS test, was significantly recovered during the
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observation period, and the forelimb-use asymmetry evaluated by cylinder test was significantly 
improved at 3 and 4 wk post transplantation compared to vehicle and GFP-NSC groups. The delayed 
recovery effect apparent for the cylinder test, unlike the NSS test, is due to features of the test. Zarruk et 
al.170 note that the cylinder test showed decreased sensitivity in mice with small infarcts, particularly
within a month after ischemia. The reduced brain infarct volume was only observed for the IL10-NSC 
group compared to the vehicle group, although there was no significant difference between the GFP-NSC 
and IL10-NSC groups. Although transplanted hNSPCs were rarely detected in the injured brain at 4 wk 
post transplantation, reduced cerebral infarct size and improved behavioral functions were observed until 
sacrifice. Our data are consistent with other studies that demonstrate the benefit of cell transplantation 
may not be due to cell replacement, and long term engraftment is not required for stem cells to exert long 
term function.25,171
IL-10 is a pluripotent cytokine with potent effects on numerous cell populations, in particular 
circulating and resident immune cells as well as epithelial and neuronal cells. Inadequate IL-10 
expression seems to have considerable pathophysiological impact. Both overexpression (e.g., in 
lymphoma, SLE, intensive care unit patients) as well as deficiency (e.g., in inflammatory bowel disease, 
psoriasis, stroke) of IL-10 are likely to have a pathophysiological significance.172 Therefore, interleukin-
10 may exhibit double-edged sword properties depending on diseases. Transgenic mice had a VMD2 
gene promoter that chronically expressed IL-10 at a much higher level than transgenic negative mice.173
The magnitude depended on the organ tissue. There was a 2-3-fold increase in the sciatic nerve 
correlating with demyelination caused by infiltrating monocyte-derived macrophages, and a 5-fold 
increase in the spinal cord dorsal roots. In the CNS, while there was a 100-fold increase of IL-10 
expression in the brain, there were no inflammatory cells, demyelination, and degradation of neural tissue 
in the CNS in general. However, the sciatic nerve demyelination, induced by long term expression of IL-
10, caused hind limb weakness and eventually paralysis in 3-mo old mice.173 This study indicated that 
high levels of IL-10 released for a chronic period of time may have detrimental peripheral neuropathy but 
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not necessarily on the CNS, such as the brain and spinal cord. Therefore, chronic administration or 
overexpression of IL-10 do not seems to pose harm locally in the CNS. However, it is still unknown 
whether long term exposure to IL-10 influences neurological development and causes side effects to the 
CNS of humans. It has become increasingly clear that appropriate expression of IL-10 may be the key to 
how IL-10 not only contributes to the delicate balance between pro- and anti-inflammatory reactions, but 
also ameliorates hypoxic-ischemic brain injury. Therefore, the precise control of transgene expression is 
desirable for many basic investigations and therapeutic applications. The expression of transgenes can be 
regulated with more sophisticated methods, such as viral vectors under control of the doxycycline-
regulated promoter.174-176 For clinical applications, further investigations are needed to understand for the 
long term treatment of IL-10 to the CNS and/or circulatory system, and well-designed human clinical 
trials are necessary to confirm the long term safety and efficacy of IL-10 for the treatment of hypoxic-
ischemic brain injury and other neurological diseases.
We postulated that these therapeutic effects of IL-10-hNSPCs on behavioral recovery and infarct 
volume could be related to alternative activation or deactivation of microglia in the ischemic brain, as 
well as neuroprotection and angiogenesis by secretary factors released from hNSPCs. From the first week 
post transplantation, resting microglia and/or deactivated microglia were increased in IL-10-hNSPCs-
transplanted mice, and these effects were sustained until sacrifice. Therefore, an important function of 
transplanted IL-10-hNSPCs might be their ability to secrete not only IL-10 but also other neurotrophic
and angiogenic factors that modulate inflammation and/or the microenvironment in the ischemic brain to 
enhance the endogenous tissue repair process.
Our results clearly show the therapeutic potential of IL-10-hNSPC treatment after neonatal HI brain 
injury for improved long term behavioral function as well as effective reduction of lesion volume. The 
therapeutic effects of IL-10-hNSPCs were associated with increased expression of neurotrophic and 
angiogenic factors, and conferred anti-inflammatory properties enhanced by IL-10.
The current study was limited in its focus on mainly inflammation of the injured brain; however, we 
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have demonstrated that intraventricular transplantation of IL-10-hNSPCs promotes immune modulation 
in the acute phase of hypoxic-ischemic brain damage in mice. Further studies are required to investigate 




Transplantation of stem cells or their derivatives, as well as the activation of endogenous stem cells 
within the brain, have been previously proposed as future therapies for neurological diseases, particularly 
HI brain injury. However, it may seem unrealistic to induce functional recovery only by replacing lost 
cells and/or protecting existing ones in neonatal brain injury. Other strategies to cure diseases are needed 
for the future.
In the present study, IL-10 expressing cells (IL-10-hNSPCs) were generated by lentiviral vector. IL-
10-hNSPCs not only reduced the expression of proinflammatory cytokines from immune cells and 
proliferation of microglial cell lines, but also promoted microglia/macrophage polarization toward M2 
cells both in vitro and in vivo. We also verified the neuroprotective effects of elevated secreted factors, 
such as NGF, NT3, NT4 and BDNF, and angiogenic effects by MMP1, MMP2 and PAI-1 elevated in IL-
10-hNSPCs. The animal model for HI brain injury was induced by ligation of the right common carotid
artery and incubated in a hypoxic atmosphere of 8% O2 and 92% N2 on postnatal day 7. IL-10-hNSPCs 
were transplanted into the ipsilateral HI-injured cerebral cortex at 3 days post injury (postnatal day 10). 
Implantation of IL-10-hNSPCs into HI mice significantly improved behavioral recovery and 
neuroprotective effect on infarct volume, as well as inhibited microglial activation, as measured by the 
area occupied with CD68-positive cells in vivo.
IL-10-hNSPCs also prevented polarization of microglia/macrophages into classically activated cells 
and promoted alternative activation of microglia/macrophages both in vitro and in vivo.
Therefore, IL-10-hNSPCs exhibited therapeutic potentials for the management of neonatal HI brain 
injury through multiple neuroprotective, angiogenic and anti-inflammatory mechanisms.
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ABSTRACT (IN KOREAN)
신생아 저산소성-허혈성 뇌손상 동물모델에서 interleukin-10 발현하는 인간 신경줄기/전구




신생아 저산소성-허혈성 뇌손상(neonatal hypoxic-ischemic brain injury)은 주산기 가
사 (perinatal asphyxia)에 의해서 신생아에서 발병하는 대표적 중증 신경계질환으로 만삭
아 1000명 출생아 중 2명에서 발병하고, 약 60%에서 신경발달 장애소견을 보인다. 현재까지
의 연구에 의하면 손상된 중추신경계의 재생은 거의 불가능하거나 극히 제한적이기 때문에
대부분의 치료는 합병증을 예방하거나 비정상적인 운동 패턴과 경직을 감소시키는데 중점을
두어왔다. 특히 저산소성-허혈성 뇌손상은 일차손상에 의해 수반되는 염증반응 혹은 싸이토
카인 발현으로 인해 뇌 손상을 유래할 수 있다고 알려져 있지만, 그 자세한 기전은 자세히
알려져 있지 않다. 신경줄기세포는 자가갱신(self-renew)하고, 신경원세포 및 신경교세포로
분화할 수 있는 분화의 다능성(multipotency)을 보이는 미성숙 신경 세포이다. 시험관 내에
서 증식되어 생체 내 이식이 가능한 신경줄기세포는 숙주 신경계에 이주, 생착, 통합되어
치료적으로 유용한 물질을 분비하고,세포구조학적 및 기능적으로도 적절한 신경세포로 분화
가능하기에 난치성 신경계 질환의 치료에 있어 잠재력을 가지고 있다.
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Interleukin-10 (IL-10)은 최초에는 싸이토카인 합성을 억제하는 인자로 소개되었고 향
후에 항염증 효과를 갖는 것이 알려졌고, 이후에 IL-10으로 명명이 되었다. 거의 모든 면역
세포에서 발현/분비하여 대부분의 면역세포에 작용하여 염증ㆍ면역반응을 조절하는 것으로
알려져 있다. 특히 IL-10은 염증성 미세아교세포/대식세포를 항염증성세포로 변화시킨다고
알려져 있으며, 직접 염증반응을 조절하여 염증성 장염(enterocolitis), 다발성경화증
(multiple sclerosis), 췌장염(pancreatitis), 당뇨병(diabetes), 내독소혈증(endotoxemia), 
관절염(arthritis), 전신성 홍반성 루푸스(systemic lupus erythematosus)와 같은 많은 질
병에서 병적 증상의 호전을 가져온다고 보고되어 있다.
본 연구에서는 IL-10을 발현하는 인간 신경줄기/전구세포를 확립하여, 신생아 저산소성
허혈성 뇌 손상 동물모델에 이식하여 세포치료 가능성을 연구하고자 하였다. 그 결과 IL-10 
발현 인간 신경줄기/전구세포는 뇌 손상 부위에 이식된 후 뇌병변 부위와 그 주변 부위로
이주하면서 생착함을 보였다. IL-10 발현 인간 신경줄기/전구세포가 이식된 실험군은 대조
군에 비해 신경학적 기능검사와 실린더 검사에서 유의한 개선된 효과를 보였다. 또한 대조
동물에 비해 실험 동물의 뇌 세포 사멸이 유의하게 감소하였고, 뇌 경색의 크기 역시 효과
적으로 감소하는 것을 확인 할 수 있었다. IL-10 발현 인간 신경줄기/전구세포는 대조군 인
간 신경줄기/전구세포와 비교하여 신경영양인자(nerve growth factor, neurotrophin 3, 
neurotrophin 4 및 brain-derived neurotrophic factor) 및 혈관생성인자(MMP1, MMP2, PAI1)
들의 발현이 크게 증가하였고, 저산소성 허혈성 조건 하에서 신경세포(SH-SY5Y cells)의 생
존율이 유의하게 개선되었다. 또한 IL-10 발현 인간 신경줄기/전구세포 뇌 이식 시 손상된
뇌 미세환경의 변화를 관찰하였는데, IL-10 발현 인간 신경줄기/전구세포는 손상된 뇌 조직
에서 염증성 싸이토카인의 발현과 활성화된 미세아교세포/대식세포의 증식을 억제하였고, 
M2형 미세아교세포/대식세포로의 분화를 촉진함을 시험관 및 뇌 손상 조직에서 확인하였다. 
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따라서 향후 IL-10 발현 인간 신경줄기/전구세포는 상기의 다양한 기전으로 신생아 저산소
성 허혈성 뇌 손상 치료에 새로운 세포유전자 치료법으로 활용될 수 있음을 제시하였다.
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